Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPB2 | Q96IY4 | 10/20 | 0.48 |
| ▸ | FNTA | P49354 | 1/20 | 0.42 |
| ▸ | FNTB | P49356 | 1/20 | 0.42 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.42 |
| ▸ | NPY5R | Q15761 | 5/20 | 0.40 |
| ▸ | NPY4R | P50391 | 5/20 | 0.40 |
| ▸ | NPY1R | P25929 | 4/20 | 0.40 |
| ▸ | LTA4H | P09960 | 1/20 | 0.39 |
| ▸ | NPY2R | P49146 | 2/20 | 0.39 |
| ▸ | NRP1 | O14786 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30417895 | 0.94 | CPB2 (0.48) | CPB2FNTAFNTBPGGT1BEPHX2 | |
| SCHEMBL31433285 | 0.88 | NPY4R (0.45) | CPB2FNTAFNTBPGGT1BNPY5R | |
| SCHEMBL30524336 | 0.85 | NPY4R (0.49) | NPY5RNPY4RNPY1RNPY2RNRP1 | |
| SCHEMBL30629198 | 0.85 | NPY4R (0.49) | NPY5RNPY4RNPY1RNPY2RNRP1 | |
| SCHEMBL30676974 | 0.85 | CPB2 (0.46) | CPB2NPY5RNPY4RNPY1RNPY2R | |
| SCHEMBL31253369 | 0.85 | CPB2 (0.46) | CPB2NPY4REPHX2 | |
| SCHEMBL30435472 | 0.83 | NPY4R (0.43) | NPY5RNPY4RNPY1RNPY2RNRP1 | |
| SCHEMBL31571450 | 0.83 | NPY4R (0.43) | NPY5RNPY4RNPY1RNPY2RNRP1 | |
| SCHEMBL29899338 | 0.83 | NPY4R (0.52) | NPY5RNPY4RNPY1RNPY2RNRP1 | |
| SCHEMBL29576757 | 0.83 | NPY4R (0.52) | NPY5RNPY4RNPY1RNPY2RNRP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025111600-A1 | COMPOSITIONS AND METHODS FOR LIPIDATED PEPTIDE-BASED MODULATORS OF HLA-E | CALICO LIFE SCIENCES LLC (US) | 2025-05-30 | — | — | WO | claimed |
| US-20250074942-A1 | COMPOSITIONS AND METHODS FOR COVALENT PEPTIDE-BASED MODULATORS OF HLA-E | CALICO LIFE SCIENCES LLC (US) | 2025-03-06 | — | — | US | claimed |
| WO-2023225350-A2 | COMPOSITIONS AND METHODS FOR COVALENT PEPTIDE-BASED MODULATORS OF HLA-E | CALICO LIFE SCIENCES LLC (US) | 2023-11-23 | — | — | WO | claimed |
| WO-2025111600-A1 | COMPOSITIONS AND METHODS FOR LIPIDATED PEPTIDE-BASED MODULATORS OF HLA-E | CALICO LIFE SCIENCES LLC (US) | 2025-05-30 | — | — | WO | disclosed |
| US-20250074942-A1 | COMPOSITIONS AND METHODS FOR COVALENT PEPTIDE-BASED MODULATORS OF HLA-E | CALICO LIFE SCIENCES LLC (US) | 2025-03-06 | — | — | US | disclosed |
| WO-2023225350-A2 | COMPOSITIONS AND METHODS FOR COVALENT PEPTIDE-BASED MODULATORS OF HLA-E | CALICO LIFE SCIENCES LLC (US) | 2023-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250074942-A1 | COMPOSITIONS AND METHODS FOR COVALENT PEPTIDE-BASED MODULATORS OF HLA-E | MICA, CD74, HLA-DRB1 | CPB2 948/4885FNTA 3629/4885FNTB 2486/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.